

MIT Open Access Articles

Esterification Delivers a Functional Enzyme into a Human Cell

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Ressler, Valerie T. et al. "Esterification Delivers a Functional Enzyme into a Human Cell." ACS Chemical Biology 14, 4 (March 2019): 599-602 © 2019 American Chemical Society

As Published: <http://dx.doi.org/10.1021/acscchembio.9b00033>

Publisher: American Chemical Society (ACS)

Persistent URL: <https://hdl.handle.net/1721.1/123443>

Version: Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

Terms of Use: Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.





Published in final edited form as:

ACS Chem Biol. 2019 April 19; 14(4): 599–602. doi:10.1021/acscchembio.9b00033.

Esterification Delivers a Functional Enzyme into a Human Cell

Valerie T. Ressler^{†,‡}, Kalie A. Mix^{‡,||}, and Ronald T. Raines^{†,‡,||,*}

[†]Department of Chemistry University of Wisconsin–Madison, Madison, Wisconsin 53706, United States


^{||}Department of Biochemistry, University of Wisconsin–Madison, Madison, Wisconsin 53706, United States

[‡]Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

Abstract

A major hurdle in chemical biology is the delivery of native proteins into the cytosol of mammalian cells. Herein, we report that esterification of the carboxyl groups of an enzyme with a diazo compound enables not only its passage into the cytosol, but also the retention of its catalytic activity there. This scenario is demonstrated with human ribonuclease 1, which manifests ribonucleolytic activity that can be cytotoxic. After internalization, the nascent esters are hydrolyzed in situ by endogenous esterases, making the process traceless. This strategy provides unprecedented opportunities for the delivery of functional enzymes into human cells.

Graphical Abstract



Biologics are driving the growth of the modern pharmacopeia.¹ Still, nearly all of these biologics are antibodies and hormones that act on the cell surface.^{2,3} Virtually none are proteins that intervene beneficially in the cytosol or nucleus, despite incalculable opportunities there.⁴

*Corresponding Author Telephone: (617) 253-1470. rtraines@mit.edu.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acscchembio.xxxx.

Experimental procedures, Figure S1 (DNA sequences), Figures S2 (amino acid sequences), and Figures S3–S7 (PDF).

The authors declare no competing financial interest.

The translocation of a putative therapeutic agent across the plasma membrane is made difficult by the high anionicity of the glycocalyx and hydrophobicity of the lipid bilayer.⁵ Any strategy for protein delivery must overcome these two obstacles. Medicinal chemists have done so by the bioreversible masking of anionic functional groups. The ensuing “prodrugs”,^{6–8} which are usually esters of carboxylic acids, constitute 20% of small-molecule drugs.⁹ Recently, we demonstrated that the esterification of the carboxyl groups of the green fluorescent protein (GFP) with 2-diazo-2-(*p*-methylphenyl)-*N,N*-dimethylacetamide enables its passage across the plasma membrane, akin to a small-molecule prodrug (Scheme 1).¹⁰ Importantly, the nascent esters are substrates for endogenous intracellular esterases.^{11,12} Thus, esterification can be a “traceless” delivery method that leaves no residual atoms attached to the cargo.

Upon cytosolic entry, esterified GFP retains its fluorescence,¹⁰ consistent with the retention of its three-dimensional structure.¹³ The catalytic activity of an enzyme is, however, the most sensitive indicator of proper conformation.¹⁴ We sought to investigate the utility of esterification as a means to promote the delivery of a functional enzyme.

As a model enzyme, we chose human ribonuclease 1 (RNase 1; EC 3.1.27.5; UniProtKB P07998).¹⁵ RNase 1 is an efficient catalyst of RNA cleavage, and its ribonucleolytic activity can be cytotoxic.^{16–18} To be cytotoxic, RNase 1 must not only enter the cytosol, but also evade the ribonuclease inhibitor protein (RI) that resides there.^{19,20} Wild-type RNase 1 forms a complex with RI that has a K_d value of (at most²¹) 0.29 fM²² and is not appreciably cytotoxic because of its sequestration by RI.²³

RI is a highly anionic protein, and its evasion is best achieved by installing anionic groups into RNase 1. Indeed, the most evasive known variant is R39D/N67D/N88A/G89D/R91D RNase 1, which has 10¹⁰-fold lower affinity for RI than does the wild-type enzyme.²² The DDADD variant is, however, not a potent cytotoxin because its anionicity deters cellular uptake.²⁴ Hence, the DDADD variant along with wild-type RNase 1 were ideal enzymes for the assessment of our approach, using cytotoxicity as a readout.

The mechanism of esterification with a diazo compound relies on a carboxyl group being in a protonated state.^{25,26} To encourage protonation, we performed esterification reactions at pH 5.5 in aqueous acetonitrile (Scheme 1). These conditions were well-tolerated by RNase 1 and its variants, and enabled esterification of $1/3$ – $1/2$ of enzymic carboxyl groups (Table 1). Esterification did reduce ribonucleolytic activity slightly (Table 1), but to a lesser extent than did the amidation of enzymic carboxyl groups.²⁷

As observed previously,²³ wild-type RNase 1 had no detectable effect on the viability of HeLa cells, even at a concentration of 100 μ M (Figure 2A). In contrast, esterification of wild-type RNase 1 engendered toxicity towards HeLa cells with an IC₅₀ value of (10 \pm 1) μ M (Figure 2A). These data are consistent with esterified RNase 1 overwhelming cytosolic RI, which is present at \sim 4 μ M.²⁹ Notably, only \sim 7% of unmodified RNase A (which is a bovine homolog of RNase 1) translocates to the cytosol from endosomes.³⁰ Accordingly, the lack of toxicity of unmodified RNase 1 along with the near-equivalence of the IC₅₀ value of

esterified RNase 1 and the cytosolic concentration of RI suggests that esterification of RNase 1 makes its cytosolic delivery efficient.

Wild-type RNase 1 has a net charge of $Z = 5$.²⁸ The unmodified enzyme enters endosomes rapidly.²⁴ In contrast, DDADD RNase 1 has a net charge of $Z = 0$ and enters endosomes slowly.²⁴ As expected, DDADD RNase 1 did not have an impact on the viability of HeLa cells (Figure 2B). In contrast, esterification made the DDADD variant cytotoxic with an IC_{50} value of $(6 \pm 1) \mu\text{M}$ (Figure 2B), despite its low k_{cat}/K_M value (Table 1). This cytotoxicity is consistent with the esterified enzyme entering the cytosol and cleaving cellular RNA there.

We were aware that the observed cytotoxicity of the esterified enzymes could be due to a property other than their catalytic activity. For example, some proteins and peptides are cytotoxic because of their ability to disrupt lipid bilayers.^{31,32} To test this alternative mechanism, we employed H12A/K41A/H119A RNase 1, which has an eviscerated active site and no detectable ribonucleolytic activity (Table 1). We found that this variant is not cytotoxic, even upon esterification (Figure 2C). Accordingly, we conclude that the cytotoxicity of both esterified wild-type RNase 1 and esterified DDADD RNase 1 relies on the manifestation of their catalytic activity within cells. We note, too, that the toxicity of these esterified enzymes for HeLa cells exceeds that of QBI-139 ($IC_{50} = 18 \pm 2 \mu\text{M}$),²³ which is an RI-evasive variant of RNase 1 that is undergoing clinical trials as a cancer chemotherapeutic agent.^{33,34}

HeLa cells, which were derived from a cervical tumor, have numerous abnormalities.³⁵ Accordingly, we sought to reproduce our results in another cell line. We chose H460 cells, which were derived from a non-small-cell lung tumor. We also used this cell line to assess the effect of esterification level on cytotoxicity. Wild-type RNase 1 and its DDADD variant were treated with either 100 or 200 equiv of diazo compound **1**. We found that increasing the esters in wild-type RNase 1 from ~ 4 to ~ 6 reduced the IC_{50} value from $(7 \pm 1) \mu\text{M}$ to $(5.1 \pm 0.5) \mu\text{M}$ (Figure 3A). Wild-type RNase 1 has 13 carboxyl groups (Figure 1), whereas the DDADD variant has 17 carboxyl groups. The larger number of carboxyl groups amplified the effects. Specifically, we found that increasing the esters in DDADD RNase 1 from ~ 7 to ~ 11 reduced the IC_{50} value from $(8.4 \pm 0.5) \mu\text{M}$ to $(1.0 \pm 0.2) \mu\text{M}$ (Figure 3B).

Finally, we investigated the reversibility of enzymic esterification in living cells. To do so, we appended an 8-residue FLAG tag to the N terminus of wild-type RNase 1 and esterified the resulting FLAG–RNase 1 by using diazo compound **1**. We treated HeLa cells with untreated or esterified FLAG–RNase 1 for 24 h, washed and lysed the cells, and recovered the FLAG–RNase 1 by using anti-FLAG magnetic beads. Mass spectrometry revealed the removal of labels by intracellular esterases (Figure S6).³⁶ These data indicate that the esters installed by diazo compound **1** are hydrolyzed by esterases in human cells.

In summary, we have used a diazo compound to esterify enzymic carboxyl groups and shown that the ensuing enzyme enters the cytosol of human cells and is functional there. Because the catalytic activity of an enzyme is fragile, its maintenance indicates that the delivery process is gentle. Notably, esterification can be performed without the need for mutagenesis,³⁷ and the modification is traceless, being removed by cellular esterases. This

facile, versatile strategy provides new opportunities for delivering native, functional proteins to intracellular targets.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding Sources

V.T.R. was supported by a William H. Peterson Fellowship in Biochemistry (Department of Biochemistry, University of Wisconsin–Madison). K.A.M. was supported by Molecular Biosciences Training Grant T32 GM007215 (NIH) and by the Broad Institute Chemical Biology and Therapeutics Science Shark Tank. This work was supported by Grants R01 GM044783 and R01 CA073808 (NIH).

REFERENCES

- (1). Mullard A Top product sales forecasts for 2018. *Nat. Rev. Drug Discov* 2018, 17, 86.
- (2). Mitragotri S; Burke PA; Langer R Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. *Nat. Rev. Drug Discov* 2014, 13, 655–672. [PubMed: 25103255]
- (3). Fu A; Tang R; Hardie J; Farkas ME; Rotello VM Promises and pitfalls of intracellular delivery of proteins. *Bioconjugate Chem.* 2014, 25, 1602–1608.
- (4). Reineke TM; Raines RT; Rotello VM Delivery of proteins and nucleic acids: Achievements and challenges. *Bioconjugate Chem.* 2019, 30, 261–262.
- (5). Du S; Liew SS; Li L; Yao SQ Bypassing endocytosis: Direct cytosolic delivery of proteins. *J. Am. Chem. Soc* 2018, 140, 15986–15996. [PubMed: 30384589]
- (6). Testa B; Mayer JM Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology. Verlag Helvetica Chimica Acta: Zürich, Switzerland, 2003.
- (7). Liederer BM; Borchardt RT Enzymes involved in the bioconversion of ester-based prodrugs. *J. Pharm. Sci* 2006, 95, 1177–1195. [PubMed: 16639719]
- (8). Lavis LD Ester bonds in prodrugs. *ACS Chem. Biol* 2008, 3, 203–206. [PubMed: 18422301]
- (9). Rautio J; Kärkkäinen J; Sloan KB Prodrugs—Recent approvals and a glimpse of the pipeline. *Eur. J. Pharm. Sci* 2017, 109, 146–161. [PubMed: 28782609]
- (10). Mix KA; Lomax JE; Raines RT Cytosolic delivery of proteins by bioreversible esterification. *J. Am. Chem. Soc* 2017, 139, 14396–14398. [PubMed: 28976737]
- (11). Liederer BM; Borchardt RT Enzymes involved in the bioconversion of ester-based prodrugs. *J. Pharm. Sci* 2006, 95, 1177–1195. [PubMed: 16639719]
- (12). Wang D; Zou L; Jin Q; Hou J; Ge G; Yang L Human carboxylesterases: A comprehensive review. *Acta Pharm. Sin. B* 2018, 8, 699–712. [PubMed: 30245959]
- (13). Waldo GS; Standish BM; Berendzen J; Terwilliger TC Rapid protein-folding assay using green fluorescent protein. *Nat. Biotechnol* 1999, 17, 691–695. [PubMed: 10404163]
- (14). Knowles JR Tinkering with enzymes: What are we learning? *Science* 1987, 236, 1252–1258. [PubMed: 3296192]
- (15). Sorrentino S The eight human “canonical” ribonucleases: Molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. *FEBS Lett.* 2010, 584, 2194–2200. [PubMed: 20388512]
- (16). Kim J-S; Sou ek J; Matoušek J; Raines RT Catalytic activity of bovine seminal ribonuclease is essential for its immunosuppressive and other biological activities. *Biochem. J* 1995, 308, 547–551. [PubMed: 7772040]
- (17). Dickson KA; Dahlberg CL; Raines RT Compensating effects on the cytotoxicity of ribonuclease A variants. *Arch. Biochem. Biophys* 2003, 415, 172–177. [PubMed: 12831839]

- (18). Rutkoski TJ; Kurten EL; Mitchell JC; Raines RT Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. *J. Mol. Biol* 2005, 354, 41–54. [PubMed: 16188273]
- (19). Leland PA; Staniszewski KE; Kim B-M; Raines RT Endowing human pancreatic ribonuclease with toxicity for cancer cells. *J. Biol. Chem* 2001, 276, 43095–43102. [PubMed: 11555655]
- (20). Rutkoski TJ; Raines RT Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. *Curr. Pharm. Biotechnol* 2008, 9, 185–189. [PubMed: 18673284]
- (21). Hoang TT; Tanrikulu IC; Vatland QA; Hoang TM; Raines RT A human ribonuclease variant and ERK-pathway inhibitors exhibit highly synergistic toxicity for cancer cells. *Mol. Cancer Ther* 2018, 17, 2622–2632. [PubMed: 30282811]
- (22). Johnson RJ; McCoy JG; Bingman CA; Phillips GN Jr.; Raines RT Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. *J. Mol. Biol* 2007, 367, 434–449.
- (23). Thomas SP; Kim E; Kim J-S; Raines RT Knockout of the ribonuclease inhibitor gene leaves human cells vulnerable to secretory ribonucleases. *Biochemistry* 2016, 55, 6359–6362. [PubMed: 27806571]
- (24). Johnson RJ; Chao T-Y; Lavis LD; Raines RT Cytotoxic ribonucleases: The dichotomy of Coulombic forces. *Biochemistry* 2007, 46, 10308–10316. [PubMed: 17705507]
- (25). Roberts JD; Watanabe W; McMahon RE The kinetics and mechanism of the reaction of diphenyldiazomethane and benzoic acid in ethanol. *J. Am. Chem. Soc* 1951, 73, 760–765.
- (26). Roberts JD; Watanabe W; McMahon RE The kinetics and mechanism of the reaction of diphenyldiazomethane with 2,4-dinitrophenol in ethanol. *J. Am. Chem. Soc* 1951, 73, 2521–2523.
- (27). Futami J; Maeda T; Kitazoe M; Nukui E; Tada H; Seno M; Kosaka M; Yamada H Preparation of potent cytotoxic ribonucleases by cationization: Enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. *Biochemistry* 2001, 40, 7518–7524. [PubMed: 11412105]
- (28). The parameter Z is defined as the number of arginine + lysine – aspartate – glutamate residues.
- (29). Haigis MC; Kurten EL; Raines RT Ribonuclease inhibitor as an intracellular sentry. *Nucleic Acids Res.* 2003, 31, 1024–1032. [PubMed: 12560499]
- (30). Chao T-Y; Raines RT Fluorogenic label to quantify the cytosolic delivery of macromolecules. *Mol. BioSyst* 2013, 9, 339–342. [PubMed: 23340874]
- (31). Rosenberg HF Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. *J. Biol. Chem* 1995, 270, 7876–7881. [PubMed: 7713881]
- (32). Leuschner C; Hansel W Membrane disrupting lytic peptides for cancer treatments. *Curr. Pharm. Des* 2004, 10, 2299–2310. [PubMed: 15279610]
- (33). Strong LE; Kink JA; Pensinger D; Mei B; Shahan M; Raines RT Efficacy of ribonuclease QBI-139 in combination with standard of care therapies. *Cancer Res.* 2012, 72 (Suppl. 1), 1838.
- (34). Strong LE; Kink JA; Mei B; Shahan MN; Raines RT First in human phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors. *J. Clin. Oncol* 2012, 30 (Suppl), TPS3113.
- (35). Landry JJM; Pyl PT; Rausch T; Zichner T; Tekkedil MM; Stütz AM; Jauch A; Aiyar RS; Pau G; Delhomme N; Gagneur J; Korbel JO; Huber W; Steinmetz LM The genomic and transcriptomic landscape of a HeLa cell line. *G3* 2013, 3, 1213–1224. [PubMed: 23550136]
- (36). Interestingly, we observed a ~160-Da mass increase for esterified FLAG-RNase 1 after its recovery from human cells (Figure S6). This increase likely results from the phosphorylation of FLAG-RNase 1 by cytosolic kinases, as has been observed with a homologous ribonuclease (Hoang, T. T.; Raines, R. T. Molecular basis for the autonomous promotion of cell proliferation by angiogenin. *Nucleic Acids Res.* 2017, 45, 818–831).
- (37). Fuchs SM; Rutkoski TJ; Kung VM; Groeschl RT; Raines RT Increasing the potency of a cytotoxin with an arginine graft. *Protein Eng. Des. Sel* 2007, 20, 505–509. [PubMed: 17954521]




Figure 1. Surface electrostatic potential of human RNase 1 (blue, positive; red, negative). The side chains of the 6 aspartate, 6 glutamate, and 4 cysteine residues are shown explicitly. The image was created with the program PyMOL from Schrödinger (New York, NY) and Protein Data Bank entry 1z7x, chain X.²²




Figure 2. Effect of esterification of human RNase 1 (A) and its variants (B, C) on the viability of HeLa cells. Cell viability was measured with a tetrazolium dye-based assay for metabolic activity. Values of IC_{50} are listed in Table 1.





Figure 3. Impact of the extent of esterification of human RNase 1 (A) and its DDADD variant (B) on the viability of H460 cells. Cell viability was measured with a tetrazolium dye-based assay for metabolic activity. Values of IC_{50} are listed in Table 1.



Scheme 1.

Table 1.

Attributes of Untreated and Esterified RNase 1 Variants

RNase 1	Z ^a	Carboxyl groups	1 (equiv) ^b	Esters ^c	k_{cat}/K_M ($10^7 M^{-1}s^{-1}$) ^d	HeLa Cells	H460 Cells	IC ₅₀ (μM) ^e
Wild-type	+5	13	0	—	2.5 ± 0.1	>100	>100	>100
Wild-type	+5	13	100	4	1.1 ± 0.5	10 ± 1	10 ± 1	7 ± 1
Wild-type	+5	13	200	6	1.6 ± 0.1	ND ^f	ND	5.1 ± 0.5
DDADD	0	17	0	—	0.022 ± 0.002	>100	>100	>100
DDADD	0	17	100	7	0.023 ± 0.003	6 ± 1	6 ± 1	8.4 ± 0.5
DDADD	0	17	200	11	0.025 ± 0.004	ND	ND	1.0 ± 0.2
H12A/K41A/H119A	+4	13	0	—	<1 × 10 ⁻⁵	>100	>100	>100
H12A/K41A/H119A	+4	13	100	4	<1 × 10 ⁻⁵	>100	>100	>100
FLAG-labeled	+2	18	0	—	0.72 ± 0.07	ND	ND	ND
FLAG-labeled	+2	18	100	5	0.35 ± 0.04	ND	ND	ND

^aRef. 28.^bReaction conditions: 200 μL of enzyme (0.14 μmol) in 10 mM MES-HCl buffer (pH 5.5) plus 200 μL of diazo compound **1** (14 or 28 μmol) in acetonitrile; 37 °C for 4 h.^cValues are the most prevalent species apparent in the mass spectra of Figures S3–S6.^dValues are the mean ± SD for the cleavage of 6-FAM-dArU(dA)2-6-TAMRA in 100 mM Tris-HCl buffer (pH 7.5), containing NaCl (100 mM). Individual values are shown in Figure S7.^eValues are the mean ± SD from data in Figures 2 and 3.^fND, not determined.